Based on the results, we may conclude that LATS expression (a) did not associate with better outcome in ovarian cancer, (b) was not reduced in SOC cell lines, and (c) was not associated with EMT status and drug sensitivity. Here, UBXN11 is linked to ovarian carcinoma.